AACR 2026: Revolution’s Next Prospect, Merck’s Reveal and a Lung Cancer Battle

Why It Matters

These data expand the pipeline of targeted and immuno‑combo therapies for lung cancer, offering investors and clinicians new options that could capture sizable market share and improve patient outcomes.

Key Takeaways

• Zoldonrasib achieved 52% response in G12D NSCLC patients.
• Median progression‑free survival reached 11.1 months, exceeding chemo benchmarks.
• Merck's MK‑2010 showed 55% response at low dose in first‑in‑human trial.
• Nuvalent's zidesamtinib delivered 71% brain‑metastasis response, indicating CNS activity.
• Ibtrozi's median response now 50 months, showing durable efficacy.

Pulse Analysis

Revolution Medicines' zoldonrasib targets the KRAS G12D mutation, a driver found in roughly 4% of NSCLC cases. By delivering a 52% objective response rate and extending progression‑free survival beyond 11 months, the drug outperforms traditional chemotherapy and rivals existing KRAS G12C inhibitors. Analysts see this as a potential catalyst for accelerated FDA approval, which could unlock a share of the more than $10 billion market for RAS‑targeted therapies. The trial’s early‑stage nature still warrants larger Phase 3 validation, but the signal is strong enough to attract heightened investor attention.

Merck's entry into the PD‑1/VEGF combination space with MK‑2010 reflects a strategic push to catch up with leaders like Akeso and Summit. The first‑in‑human study in China reported a 55% response rate at the lower dose, comparable to competitors, though safety signals such as hypertension and proteinuria remain notable. While the data lack a clear differentiator, they re‑establish Merck as a contender in the burgeoning bispecific arena, where the convergence of immunotherapy and anti‑angiogenesis could reshape treatment algorithms for PD‑L1‑positive lung cancer.

The ROS1 niche, representing about 2% of NSCLC patients, is witnessing renewed competition from Nuvation's Ibtrozi and Nuvalent's zidesamtinib. Both agents demonstrate impressive durability—50‑month median response for Ibtrozi and over 15‑month disease control for zidesamtinib—while also showing activity against brain metastases, a critical unmet need. These advancements may revive commercial optimism for ROS1 inhibitors, encouraging clinicians to consider newer options over older, less effective drugs. Collectively, the AACR revelations underscore a broader shift toward precision‑focused, combination regimens that promise both clinical benefit and significant revenue potential for biotech and pharma players alike.